Leerink Partnrs Forecasts Envista’s Q3 Earnings (NYSE:NVST)

Envista Holdings Co. (NYSE:NVST) – Research analysts at Leerink Partnrs lowered their Q3 2025 earnings per share estimates for Envista in a note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst M. Cherny now forecasts that the company will post earnings of $0.26 per share for the quarter, down from their previous estimate of $0.30. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Envista’s current full-year earnings is $0.72 per share. Leerink Partnrs also issued estimates for Envista’s Q4 2025 earnings at $0.29 EPS, FY2025 earnings at $0.98 EPS and FY2026 earnings at $1.27 EPS.

Envista (NYSE:NVST) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.01. Envista had a positive return on equity of 3.76% and a negative net margin of 53.42%.

Several other equities research analysts have also issued reports on NVST. Piper Sandler lifted their price objective on Envista from $17.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday. Jefferies Financial Group lifted their price objective on Envista from $20.00 to $22.00 and gave the company a “hold” rating in a research note on Thursday, January 23rd. Leerink Partners raised Envista from an “underperform” rating to a “market perform” rating and lifted their price objective for the company from $16.00 to $23.00 in a research note on Thursday, October 31st. Mizuho started coverage on Envista in a research note on Wednesday, December 4th. They set an “underperform” rating and a $20.00 price target for the company. Finally, Stifel Nicolaus lifted their price target on Envista from $18.00 to $21.00 and gave the stock a “buy” rating in a research note on Wednesday, October 23rd. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $20.21.

Envista Trading Up 5.8 %

NYSE:NVST opened at $21.76 on Friday. Envista has a 52-week low of $15.15 and a 52-week high of $24.79. The stock has a fifty day moving average of $19.97 and a 200 day moving average of $19.10. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.08 and a quick ratio of 1.77.

Hedge Funds Weigh In On Envista

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Iron Triangle Partners LP bought a new position in shares of Envista during the 3rd quarter valued at $43,262,000. Point72 Asset Management L.P. bought a new position in shares of Envista during the 3rd quarter valued at $37,559,000. Polar Asset Management Partners Inc. lifted its holdings in shares of Envista by 375.6% during the 3rd quarter. Polar Asset Management Partners Inc. now owns 1,497,250 shares of the company’s stock valued at $29,586,000 after buying an additional 1,182,450 shares during the period. Franklin Resources Inc. lifted its holdings in shares of Envista by 26.5% during the 3rd quarter. Franklin Resources Inc. now owns 3,971,662 shares of the company’s stock valued at $78,480,000 after buying an additional 830,861 shares during the period. Finally, Hotchkis & Wiley Capital Management LLC purchased a new stake in shares of Envista in the 3rd quarter worth $14,965,000.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.